$PBLA
Panbela Therapeutics, Inc.

2016 Form 10-K Financial Statement

#000143774917005554 Filed on March 30, 2017

View on sec.gov

Income Statement

Concept 2016 2015 Q4 2015
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.660M $370.0K $2.590M
YoY Change 2.7% 54.17% 139.81%
% of Gross Profit
Research & Development $2.504M $920.0K $2.852M
YoY Change -12.2% 37.31% 20.54%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.504M $1.280M $2.852M
YoY Change -12.2% 39.13% 20.54%
Operating Profit -$5.168M -$5.444M
YoY Change -5.07% 58.03%
Interest Expense $180.0K -$60.00K $183.0K
YoY Change -1.64% -14.29% -0.54%
% of Operating Profit
Other Income/Expense, Net -$285.0K -$20.00K -$239.0K
YoY Change 19.25% -33.33% 23.2%
Pretax Income -$5.453M -$1.370M -$5.683M
YoY Change -4.05% 34.31% 56.17%
Income Tax -$341.0K -$640.0K -$756.0K
% Of Pretax Income
Net Earnings -$5.112M -$730.0K -$4.927M
YoY Change 3.75% -25.51% 39.54%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.643M -$237.8K -$3.496M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2016 2015 Q4 2015
SHORT-TERM ASSETS
Cash & Short-Term Investments $440.0K $930.0K $930.0K
YoY Change -52.69% -56.74% -56.74%
Cash & Equivalents $440.0K $925.0K $930.0K
Short-Term Investments
Other Short-Term Assets $120.0K $70.00K $70.00K
YoY Change 71.43% 250.0% 250.0%
Inventory
Prepaid Expenses $74.00K
Receivables
Other Receivables
Total Short-Term Assets $880.0K $1.732M $1.730M
YoY Change -49.13% -27.01% -27.0%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $76.00K
YoY Change -27.62%
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL ASSETS
Total Short-Term Assets $880.0K $1.732M $1.730M
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $880.0K $1.732M $1.730M
YoY Change -49.13% -30.1% -30.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.250M $585.0K $590.0K
YoY Change 111.86% 96.97% 96.67%
Accrued Expenses $1.000M $505.0K $540.0K
YoY Change 85.19% 282.58% 217.65%
Deferred Revenue
YoY Change
Short-Term Debt $250.0K $250.0K $250.0K
YoY Change 0.0%
Long-Term Debt Due $3.030M
YoY Change
Total Short-Term Liabilities $5.520M $1.375M $1.380M
YoY Change 300.0% 194.43% 193.62%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $287.0K $3.000M
YoY Change -100.0% -4.33% -9.09%
Other Long-Term Liabilities $0.00 $40.00K $40.00K
YoY Change -100.0% 33.33% 33.33%
Total Long-Term Liabilities $0.00 $3.038M $3.040M
YoY Change -100.0% -8.69% -8.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.520M $1.375M $1.380M
Total Long-Term Liabilities $0.00 $3.038M $3.040M
Total Liabilities $5.520M $4.413M $4.410M
YoY Change 25.17% 16.32% 16.36%
SHAREHOLDERS EQUITY
Retained Earnings -$13.67M
YoY Change 59.49%
Common Stock $30.00K
YoY Change 400.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.640M -$2.681M -$2.680M
YoY Change
Total Liabilities & Shareholders Equity $880.0K $1.732M $1.730M
YoY Change -49.13% -30.1% -30.24%

Cashflow Statement

Concept 2016 2015 Q4 2015
OPERATING ACTIVITIES
Net Income -$5.112M -$730.0K -$4.927M
YoY Change 3.75% -25.51% 39.54%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.398M -$860.0K -$3.900M
YoY Change -38.51% -26.5% 16.42%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $500.0K
YoY Change -100.0% -100.0% -200.0%
Cash From Investing Activities $0.00 $0.00 $500.0K
YoY Change -100.0% -100.0% -200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $1.513M
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.915M 0.000 2.680M
YoY Change -28.54% -100.0% -4.96%
NET CHANGE
Cash From Operating Activities -2.398M -860.0K -3.900M
Cash From Investing Activities 0.000 0.000 500.0K
Cash From Financing Activities 1.915M 0.000 2.680M
Net Change In Cash -483.0K -860.0K -720.0K
YoY Change -32.92% -31.75% -30.1%
FREE CASH FLOW
Cash From Operating Activities -$2.398M -$860.0K -$3.900M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015 snbp Adjustments To Additional Paid In Capital Warrants Exercised
AdjustmentsToAdditionalPaidInCapitalWarrantsExercised
375000
CY2016 snbp Adjustments To Additional Paid In Capital Warrants Exercised
AdjustmentsToAdditionalPaidInCapitalWarrantsExercised
42000
CY2016Q4 snbp Capital Stock Shares Authorized
CapitalStockSharesAuthorized
220000000
CY2016Q4 snbp Common Shares Issued Upon Conversion Of Notes Payable
CommonSharesIssuedUponConversionOfNotesPayable
2466667
CY2016Q3 snbp Deferred Compensation Exchanged For Common Stock And Warrants
DeferredCompensationExchangedForCommonStockAndWarrants
196000
CY2016 snbp Deferred Compensation Exchanged For Common Stock And Warrants
DeferredCompensationExchangedForCommonStockAndWarrants
196000
CY2015 snbp Deferred Compensation Exchanged For Common Stock And Warrants
DeferredCompensationExchangedForCommonStockAndWarrants
CY2016 snbp Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.04
CY2015 snbp Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.103
CY2016 snbp Effective Income Tax Rate Reconciliation State Tax True Up Rate Percent
EffectiveIncomeTaxRateReconciliationStateTaxTrueUpRatePercent
0.006
CY2015 snbp Effective Income Tax Rate Reconciliation State Tax True Up Rate Percent
EffectiveIncomeTaxRateReconciliationStateTaxTrueUpRatePercent
0.053
CY2016 snbp Increase Decrease In Income And Other Taxes Receivable
IncreaseDecreaseInIncomeAndOtherTaxesReceivable
-426000
CY2015 snbp Increase Decrease In Income And Other Taxes Receivable
IncreaseDecreaseInIncomeAndOtherTaxesReceivable
610000
CY2016Q4 snbp Interest Payable Noncurrent
InterestPayableNoncurrent
CY2015Q4 snbp Interest Payable Noncurrent
InterestPayableNoncurrent
39000
CY2015Q3 snbp Merger Agreement Ownership Percentage By Former Shareholders
MergerAgreementOwnershipPercentageByFormerShareholders
0.988
CY2015Q3 snbp Merger Number Of Shares Called By Rights
MergerNumberOfSharesCalledByRights
28442484
CY2015Q3 snbp Merger Number Of Shares For Every Cancelled Share
MergerNumberOfSharesForEveryCancelledShare
4
CY2015 snbp Warrant Exercise Price Adjustment
WarrantExercisePriceAdjustment
CY2016Q4 snbp Working Capital
WorkingCapital
-4600000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1245000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
585000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
842000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
505000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
76000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
13000
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
14029000
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
10943000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
933000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
902000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
557000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
70000
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
75000
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
42000
CY2016 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
12000
CY2015 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
10000
CY2016 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
28000
CY2015 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
28000
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13101267
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8480267
CY2016Q4 us-gaap Assets
Assets
877000
CY2015Q4 us-gaap Assets
Assets
1732000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
877000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
1732000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
438000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
925000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1654000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-487000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-729000
CY2015Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2550000
CY2016Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3615000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
24245267
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32201306
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29892806
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32201306
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29892806
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
32000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
30000
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5049000
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4897000
CY2016 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 9pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Concentration of </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">c</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">redit </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">r</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">isk</div></div></div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Financial instruments that potentially subject the company to significant concentrations of credit risk consist primarily of cash. Cash is deposited in demand accounts at commercial banks. At times, such deposits <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> be in excess of insured limits. The Company has not experienced any losses on its deposits of cash.</div></div></div></div></div></div></div></div>
CY2016Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
CY2015Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
287000
CY2016 us-gaap Nature Of Operations
NatureOfOperations
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.</div>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Risks and Uncertainties</div></div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration (&#x201c;FDA&#x201d;) in the United States, the Therapeutic Goods Administration (&#x201c;TGA&#x201d;) in Australia, the European Medicines Agency (&#x201c;EMA&#x201d;) in the European Union, and comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> take many years, and is normally expected to involve substantial expenditures.</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We have incurred losses of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$18.8</div> million since our inception in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011.</div> For the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> we incurred a net loss and negative cash flows from operating activities of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.1</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.4</div> million, respectively. We expect to incur substantial losses for the foreseeable future, which will continue to generate negative net cash flows from operating activities, as we continue to pursue research and development activities and seek to commercialize our primary product candidate, SBP-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">101</div></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> we had cash of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$438,000,</div> negative working capital of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.6</div> million and stockholders&#x2019; deficit of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.6</div> million. In addition, as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company had not paid the required quarterly interest payments for its convertible notes payable for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">second,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">fourth</div> quarters of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div> This constitutes an event of default under which the note holders <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> demand immediate payment of the outstanding principal and accrued but unpaid interest. See Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div> entitled &#x201c;Indebtedness.&#x201d; The Company&#x2019;s principal sources of cash have included the issuance of convertible debt and equity securities. </div></div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</div></div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The accompanying Consolidated Financial Statements have been prepared assuming that we will continue as a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business and do not include any adjustments relating to the recoverability or classification of assets or the amounts of liabilities that might result from the outcome of these uncertainties. Our ability to continue as a going concern, realize the carrying value of our assets and discharge our liabilities in the ordinary course of business is dependent upon a number of factors, including our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for our initial product candidate, SBP-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">101,</div> in the United States, Australia, the European Union or other markets and ultimately our ability to market and sell our initial product candidate. These factors, among others, raise substantial doubt about our ability to continue operations as a going concern. See Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> entitled &#x201c;Liquidity and Management&#x2019;s Plans.&#x201d;</div></div></div>
CY2015 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
226000
CY2016Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
CY2015Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
2712000
CY2016Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
2733000
CY2015Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
CY2016 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
4472000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
3811000
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3550000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3395000
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
79000
CY2015Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
32000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Foreign
DeferredTaxAssetsTaxCreditCarryforwardsForeign
235000
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Foreign
DeferredTaxAssetsTaxCreditCarryforwardsForeign
236000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
420000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
148000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
188000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
4472000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3811000
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2016 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-4000
CY2015 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-7000
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.307
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.29
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.001
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.001
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.001
CY2016Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1900000
CY2015Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
0
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2664000
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2592000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-5453000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-5683000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-341000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-756000
CY2016Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
321000
CY2015Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
733000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
726000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
252000
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
601000
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
419000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-19000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
45000
CY2016 us-gaap Interest Expense
InterestExpense
180000
CY2015 us-gaap Interest Expense
InterestExpense
183000
CY2016 us-gaap Interest Paid
InterestPaid
57000
CY2015 us-gaap Interest Paid
InterestPaid
145000
CY2016Q4 us-gaap Interest Payable Current
InterestPayableCurrent
155000
CY2015Q4 us-gaap Interest Payable Current
InterestPayableCurrent
35000
CY2016 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
2000
CY2015 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
8000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
877000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1732000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5519000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1375000
CY2016Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
CY2015Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3038000
CY2016Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
294000
CY2015Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1915000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2675000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-4927000
CY2016 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
CY2015 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
500000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
762000
CY2016 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
42000
CY2015 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
400000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2504000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2852000
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.32
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.51
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
500000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2398000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3897000
us-gaap Net Income Loss
NetIncomeLoss
-18800000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-5112000
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-285000
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-239000
CY2015Q3 us-gaap Notes Assumed1
NotesAssumed1
250000
CY2016 us-gaap Notes Assumed1
NotesAssumed1
CY2015 us-gaap Notes Assumed1
NotesAssumed1
250000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-5168000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-5444000
CY2016 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
63000
CY2015 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
30000
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-107000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-64000
CY2016 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
152000
CY2015 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
12000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
74000
CY2013Q4 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
3100000
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1513000
CY2016 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
1873000
CY2015 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
118000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-18779000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13667000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
902000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
976000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.75
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
11144000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4035600
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.54
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
4773616
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
300000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5340000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3856000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.95
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3900000
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5043600
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5487752
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3463600
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7019600
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.24
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.27
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.95
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.20
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.22
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.32
CY2016Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
4035600
CY2016Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
7019600
CY2016Q4 us-gaap Share Price
SharePrice
1.51
CY2015Q4 us-gaap Share Price
SharePrice
0.32
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2015Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
0
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
2984000
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
0
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
0
CY2015Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0.95
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
872000
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
0.95
CY2016 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P8Y25D
CY2016Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
0.95
CY2016 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P8Y25D
CY2016 us-gaap Stock Issued1
StockIssued1
75000
CY2015 us-gaap Stock Issued1
StockIssued1
CY2016Q1 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
37500
CY2015Q1 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
132964
CY2015 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2590536
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
CY2015 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
-250000
CY2015 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
226000
CY2015 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
42000
CY2016 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
75000
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1513000
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2069000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
693000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-4642000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-2681000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-1316000
CY2016Q4 us-gaap Unsecured Debt Current
UnsecuredDebtCurrent
250000
CY2015Q4 us-gaap Unsecured Debt Current
UnsecuredDebtCurrent
250000
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31068765
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14073174
CY2016 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 9pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of estimates</div></div></div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The preparation of Consolidated Financial Statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</div></div></div></div></div></div></div></div>

Files In Submission

Name View Source Status
0001437749-17-005554-index-headers.html Edgar Link pending
0001437749-17-005554-index.html Edgar Link pending
0001437749-17-005554.txt Edgar Link pending
0001437749-17-005554-xbrl.zip Edgar Link pending
a1.jpg Edgar Link pending
a2.jpg Edgar Link pending
a3.jpg Edgar Link pending
ex10-7.htm Edgar Link pending
ex10-7img001.gif Edgar Link pending
ex21-1.htm Edgar Link pending
ex23-1.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snbp-20161231.xml Edgar Link completed
snbp-20161231.xsd Edgar Link pending
snbp-20161231_cal.xml Edgar Link unprocessable
snbp-20161231_def.xml Edgar Link unprocessable
snbp-20161231_lab.xml Edgar Link unprocessable
snbp-20161231_pre.xml Edgar Link unprocessable
snbp20161231_10k.htm Edgar Link pending